Evaluation of the Effects of Extracorporeal Membrane Oxygenation on Antiepileptic Drug Serum Concentrations in Pediatric Patients.

OBJECTIVES Patients supported on extracorporeal membrane oxygenation (ECMO) have an increased incidence of seizures. Phenobarbital (PB) and fosphenytoin (fos-PHT) are common antiepileptic drugs (AEDs) used to manage seizures in the pediatric population; however, it is unknown what effect ECMO has on the serum concentrations of AEDs. The purpose of this study is to evaluate the effect of ECMO on AED serum concentrations. METHODS A retrospective, matched-cohort study was performed in patients younger than 18 years who received ECMO and were treated with intravenous (IV) PB or fos-PHT at Texas Children's Hospital between 2004 and 2014. Patients receiving IV AED therapy and ECMO were matched, based on age, sex, and weight, with patients receiving IV AED therapy without ECMO. The 24-hour cumulative AED dose, serum concentrations, number of doses per serum concentration drawn ratio, volume of distribution, therapeutic serum concentrations, and time to therapeutic serum concentration were compared between both groups. The fos-PHT and PB groups were analyzed in all patients and in neonates only. RESULTS Fourteen patients met inclusion criteria. The fos-PHT neonatal (20.1 vs 11.3 mg/kg/day, p = 0.044), PB composite (33.9 vs 21.6 mg/kg/day, p = 0.012), and PB neonatal (40.3 vs 20 mg/kg/day, p = 0.04) had larger 24-hour cumulative doses compared with non-ECMO patients. Lower serum concentrations were observed in the PB composite ECMO group (19.1 vs 35.4 mg/L, p < 0.001) and the PB neonatal ECMO group (20.5 vs 27.8 mg/L, p = 0.01) compared with non-ECMO patients. CONCLUSION Pediatric patients receiving PB on ECMO and neonatal patients receiving fos-PHT on ECMO required larger doses, and in pediatric patients achieved lower serum concentrations, suggesting the necessity for alternative dosing strategies in these populations.

[1]  B. Bruguerolle,et al.  Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach , 2014, Fundamental & clinical pharmacology.

[2]  Peter C. Laussen,et al.  The Association of Carotid Artery Cannulation and Neurologic Injury in Pediatric Patients Supported With Venoarterial Extracorporeal Membrane Oxygenation* , 2014, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[3]  L. Ibsen,et al.  Neurologic complications and neurodevelopmental outcome with extracorporeal life support. , 2013, World journal of critical care medicine.

[4]  David Wypij,et al.  Neurologic complications in neonates supported with extracorporeal membrane oxygenation. An analysis of ELSO registry data , 2013, Intensive Care Medicine.

[5]  J. Arnold,et al.  Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment , 2007, Intensive Care Medicine.

[6]  A. Cranendonk,et al.  Clinical pharmacokinetics of phenobarbital in neonates. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[7]  M. Buck,et al.  Phenobarbital Dosing and Pharmacokinetics in a Neonate Receiving Extracorporeal Membrane Oxygenation , 1999, The Annals of pharmacotherapy.

[8]  G. Koren,et al.  Preliminary Studies of the Effects of Extracorporeal Membrane Oxygenator on the Disposition of Common Pediatric Drugs , 1993, Therapeutic drug monitoring.

[9]  J. Tobias,et al.  Phenobarbital use in an infant requiring extracorporeal membrane life support , 2013, Journal of anaesthesiology, clinical pharmacology.

[10]  Michael E. Winter,et al.  Basic Clinical Pharmacokinetics , 1980 .